{"id":1913,"date":"2024-12-21T16:57:10","date_gmt":"2024-12-21T13:57:10","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=1913"},"modified":"2025-06-21T13:49:54","modified_gmt":"2025-06-21T10:49:54","slug":"uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/uk-approves-givinostat-duvyzat-for-duchenne-muscular-dystrophy-treatment\/","title":{"rendered":"El Reino Unido aprueba el uso de Givinostat (Duvyzat) para el tratamiento de la distrofia muscular de Duchenne"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This approval, announced on 20 December 2024, marks a crucial step forward in the treatment of this debilitating genetic disorder.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Givinostat is a nonsteroidal drug indicated for the treatment of patients aged 6 years of age and older with all genetic variants of DMD. [Read more: <a href=\"https:\/\/dmdwarrior.com\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"1462\" rel=\"noreferrer noopener\">What is Duvyzat (Givinostat)?<\/a>]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD). In a significant development for patients with Duchenne muscular dystrophy (DMD), the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation for the medicine givinostat, also known as Duvyzat. This approval, announced on 20 December 2024, marks a crucial step [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1916,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[45],"tags":[46,49,47,50,48],"class_list":["post-1913","post","type-post","status-publish","format-standard","has-post-thumbnail","category-approved-therapies-for-duchenne-muscular-dystrophy","tag-duvyzat","tag-england","tag-givinostat","tag-mhra","tag-uk"],"subtitle":"La aprobaci\u00f3n condicional de la MHRA permite el uso de givinostat en pacientes con DMD de seis a\u00f1os de edad o m\u00e1s, y es aplicable a todas las variantes gen\u00e9ticas de la enfermedad. Esta decisi\u00f3n sigue a la aprobaci\u00f3n de givinostat por parte de la Administraci\u00f3n de Alimentos y Medicamentos de los Estados Unidos (FDA) a principios de este a\u00f1o.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/1913","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/1916"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}